登录新浪财经APP 搜索【信披】查看更多考评等级 董秘回答(长春高新SZ000661)： 您好，经营情况请关注公司定期报告等，对于相关新产品公司会根据政策要求、行业、市场等情况合理 确定销售政策，目前暂时无法预测未来相关情况；控股股东股权结构变化是基于优化国有企业资源配置 方面做出的，不会对公司的正常经营活动产生影响，未来如有其他达到信息披露标准的情况公司会履行 信息披露义务。谢谢！查看更多董秘问答>> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 投资者提问： 董秘好！目前省联盟已对长效生长激素集采，降价明显，随着竞品公司同类产品出现，大概何时全国性 的长效生长激素集采，届时对长春高新的净利润会产生多大的影响（会腰斩甚至脚斩吗），那个时候长 春高新的非生长激素产品能及时补充这个利润缺口吗，其痛风药何时进入医保，痛风药能产生多大的营 收和利润？近段时间，长春高新控股股东百分之十九的股权变动，新进入的新区产投，能对长春高新有 多大的精准资源支撑 ...

证券研究报告 | 2025年11月04日 特宝生物（688278.SH） 优于大市 核心产品派格宾慢乙肝功能性治愈适应症获批 资料来源：Wind、国信证券经济研究所预测 注：摊薄每股收益按最新总股本计算 核心观点 公司研究·财报点评 医药生物·生物制品 证券分析师：马千里 证券分析师：陈曦炳 S0980521070001 S0980521120001 三季度营收维持环比双位数增长。2025 年前三季度，公司实现营收 24.80 亿元（+26.9%），归母净利润 6.66 亿元（+20.2%）。 分季度看，2025Q1/Q2/Q3 分别实现营收 6.73/8.37/9.69 亿元（分别同 比+23.5%/+29.9%/+26.7%，Q2/Q3 分别环比+24.3%/+15.7%）,归母净 利润 1.82/2.46/2.38 亿元（分别同比+41.4%/+40.0%/-4.6%，Q2/Q3 分 别环比+34.9%/-3.1%）。 核心产品派格宾慢乙肝功能性治愈适应症获批。2025 年 10 月 13 日，公司 聚乙二醇干扰素α-2b 注射液（商品名：派格宾）获得国家药监局批准联合 核苷（酸）类似物用于成人慢性乙型 ...

Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of 9.807 billion CNY, a decrease of 5.60% year-on-year [3] - Net profit attributable to shareholders was 1.165 billion CNY, down 58.23% compared to the previous year [3] - Subsidiary JinSai Pharmaceutical generated revenue of 8.213 billion CNY, a slight increase of 0.61%, but net profit decreased by 49.96% to 1.421 billion CNY [3] - Subsidiary Baike Bio reported revenue of 474 million CNY, a significant decline of 53.76%, with a net loss of 158 million CNY, down 164.76% [3] - Subsidiary Huakang Pharmaceutical's revenue was 542 million CNY, down 5.38%, with a net profit of 36 million CNY, an increase of 2.46% [3] - Subsidiary Gaoxin Real Estate achieved revenue of 544 million CNY, a decrease of 7.97%, with a net profit of 23,700 CNY, down 99.39% [3] New Product Developments - JinBeiXin (伏欣奇拜单抗), a new treatment for acute gouty arthritis, was launched in July 2025, generating over 55 million CNY in sales by Q3 2025 [5] - The product MeSiYa, targeting cancer-related cachexia, achieved nearly 100 million CNY in sales during the first three quarters of 2025 [5] - The company is focusing resources on promoting new products with high market potential to drive future growth [5] Collaborations and Partnerships - The company has partnered with ALK-Abelló A/S to expand its product pipeline in the respiratory allergy field, leveraging its sales channels for rapid promotion [6] - The collaboration includes both injectable and tablet forms of desensitization products, with plans to expedite clinical trials for the tablet version [6] Research and Development Pipeline - The company is advancing clinical trials in traditional areas like endocrine metabolism and women's health, as well as innovative directions in oncology and immunology [7] - Key projects include: - GenSci134, a long-acting growth hormone for adults, currently in Phase I trials [8] - GenSci098, a TSHR antagonist for thyroid conditions, progressing through Phase I trials [8] - GenSci120, a PD-1 agonist, expected to enter Phase II trials in early 2026 [8] - Multiple antibody-drug conjugates (BsADC) for various cancers are in the pipeline, with clinical trial applications submitted [8] H Share Listing Progress - The company submitted its H Share listing application to the Hong Kong Stock Exchange at the end of September 2025, receiving regulatory acceptance in mid-October [9]

Summary of the Conference Call for Jichuan Pharmaceutical Company Overview - **Company**: Jichuan Pharmaceutical - **Date**: October 27, 2025 Key Points Financial Performance - **Revenue**: Q3 revenue decreased by 33% year-on-year, totaling 11.8 billion CNY, with a total revenue of 39.32 billion CNY for the first three quarters, also down 32% [2][3] - **Net Profit**: Net profit attributable to shareholders fell by 47% to 2.98 billion CNY in Q3, and 46% to 10.2 billion CNY for the first three quarters [2][3] - **Non-recurring Profit**: Non-recurring net profit decreased by 54% to 2.39 billion CNY in Q3, and 49% to 8.6 billion CNY for the first three quarters [2][3] - **Cost of Sales**: Operating costs decreased by 23% year-on-year, with Q3 costs at 2.6 billion CNY, down 30% [9] Product Performance - **Key Products**: - Sales of potassium sulfate increased by 25% year-on-year, reaching 1.1 billion CNY in Q3 [4] - Sales of phenylephrine hydrochloride reached 40 million CNY in Q3, totaling 80 million CNY for the first three quarters [5] - **Retail Sales**: Retail sales maintained a healthy inventory level, achieving a completion rate of 100% in September and October, with monthly sales around 2-3 billion CNY [6] New Product Developments - **Innovative Drugs**: - Adult indications for the flu product have been approved, with adolescent indications expected to be approved in H1 2026 [7] - Long-acting growth hormone expected to be commercialized by early 2028 [7] - NDA for post-operative intestinal recovery product LB1,148 expected in June 2026 [7] - Pediatric constipation granules NDA accepted, with several other products in various stages of clinical trials [7] Cost and Expense Management - **Gross Margin**: Gross margin decreased by 0.9 percentage points year-on-year but increased by 3.9 percentage points quarter-on-quarter [9] - **Expense Ratios**: - Sales expense ratio at 34%, down 3.7 percentage points year-on-year; management expense ratio at 8.2%, up 3 percentage points; R&D expense ratio at 6.9%, up 1.8 percentage points [9] Market Outlook - **Q4 and 2026 Projections**: - Q4 expected to see a market recovery with a narrowing decline; 2026 revenue growth target set at single digits, with higher profit growth anticipated [11] - **Essential Drug Directory**: The essential drug directory project is expected to be completed this year, potentially benefiting the company’s pediatric products [12] Competitive Landscape - **Market Share**: The company retained half of the market share for potassium sulfate after successful bidding in the centralized procurement [4][17] - **New Product Launches**: The company is focusing on innovative marketing strategies for flu drugs, with plans for significant sales during the flu season [13][14] Dividend Policy - **Dividend Expectations**: The company aims to maintain a stable dividend level despite a decline in performance this year, with efforts to ensure satisfactory returns for shareholders [10] Inventory Management - **Inventory Levels**: Retail inventory is estimated at 1-2 billion CNY, equivalent to about one month of sales, while hospital inventory remains stable at around 40 days [9] Future Strategies - **R&D Focus**: The company is building an innovative drug R&D team, focusing on small molecule drugs and exploring new technology directions [16] Conclusion - **Overall Sentiment**: Despite facing significant challenges in 2025, the company expresses confidence in future performance driven by new product launches and market recovery strategies [25]

Summary of Jichuan Pharmaceutical Conference Call Company Overview - Jichuan Pharmaceutical is currently positioned with a high cost-performance ratio, indicating a favorable future trend for investors to focus on and allocate resources towards [2][3] Key Products and Sales Strategies - The company launched the product "Jike Shun" in July 2025, which has received online sales permission from JD Health. An increase in flu incidence in Q4 is expected to boost its sales [2][4] - Key products include: - "Pudilan Oral Liquid" focusing on expanding the outpatient market - "Children's Chiqiao Qingre Granules," an exclusive pediatric product - The company also has secondary products such as "Huanglong Cough Granules," "San'ao Tablets," and "Chaihu Granules," forming a strong product matrix in the respiratory field, reinforcing its leading position in OTC channels and pediatrics [5] Research and Development Pipeline - The company has ongoing research pipelines, including PDE4 and long-acting growth hormone products, which are in the late stages of development and warrant attention for their progress [2][4] Financial Performance and Cash Flow - As of now, the company has nearly 10 billion in cash reserves, with a projected dividend payout ratio of 76% for 2024. This financial strength supports the investment case for Jichuan Pharmaceutical [6] Regulatory Environment and Market Impact - The recent revisions to the national essential drug management measures are expected to advance in Q4 or after the next National People's Congress, potentially enhancing inpatient volumes. The market's expectations in this regard are not yet fully realized, making it a point of interest for investors [7] Overall Market Outlook - Despite a significant decline in the first half of 2024 due to high comparative bases, the third quarter showed improvement, indicating a positive trend for the company's overall profitability moving forward [3]

Summary of Key Points from the Conference Call Industry Overview - The pharmaceutical sector in China is driven by innovative drugs, particularly companies with Business Development (BD) and Technical Services (TS) capabilities, leading to a BD-driven bull market for innovative drugs [1][2][10] - The Chinese pharmaceutical industry benefits from advantages such as an engineer dividend, rapid clinical advancement, and low costs, making it competitive in areas like dual antibodies, triple antibodies, and weight loss drugs [1][4][5] Core Insights and Arguments - The innovative drug sector receives policy support across research, payment, and commercialization, with high-end commercial insurance and medical insurance covering innovative drugs, encouraging rapid market entry post-approval [1][11] - The CRO (Contract Research Organization) industry is benefiting from the return of BD funds, with significant investments in innovative drug research, leading to strong performances from companies like WuXi AppTec and Kelun [1][13] - The medical device sector is characterized by high competition in traditional devices, while innovative devices like robots and endoscopes are in an import substitution phase, with market rotation favoring companies with new products [1][12] Investment Opportunities - Current and future investment opportunities are concentrated in innovative drugs, CROs, and consumer healthcare sectors, with companies like Heng Rui Medicine and BeiGene emerging as leaders in the previous bull market [7][10] - The focus on innovative drugs is expected to continue, with significant potential in PD-1 upgrade technology platforms and breakthroughs in areas like oncology, diabetes, and autoimmune diseases [3][15] Market Trends and Dynamics - The pharmaceutical industry has undergone significant changes, with a shift from pandemic-related demand to a focus on innovative drugs, particularly after a downturn in the market over the past four to five years [2][10] - The global pharmaceutical market is seeing a surge in interest in oncology, weight loss, and autoimmune diseases, with Chinese companies achieving upgrades through diligent restructuring and accelerated clinical progress [17][20] Challenges and Risks - The consumer healthcare sector faces challenges due to economic changes leading to price sensitivity among consumers, particularly in dental services and blood products, which are affected by strict hospital prescription regulations [14][30] - The CRO industry has faced difficulties due to poor financing data and reduced orders, although there are signs of recovery driven by BD funding [13][25] Future Outlook - The innovative drug market is expected to see a rise in the proportion of innovative drug spending from approximately 5%-11% to potentially 20% in the future, supported by national policies [21] - The medical device market is stable, with significant players in the U.S., Switzerland, and China, while domestic companies are encouraged to enhance their competitiveness through innovation and international collaboration [23][28] Conclusion - The focus on innovative companies and essential medical products is crucial for future growth, with a global perspective on valuation comparisons to uncover more investment opportunities [9][10]

Core Viewpoint - Anke Bio has been actively involved in the reproductive health sector for years, with a comprehensive product range from reproductive testing to therapeutic drugs, and aims to leverage a partnership with Baoji Pharmaceutical for market expansion [1] Group 1: Company Strategy - The company has established a dedicated reproductive and antiviral division to promote market segmentation and enhance product visibility [1] - A specialized team of over 300 members is in place to support the marketing efforts for the long-acting follicle-stimulating hormone once it is launched [1] Group 2: Product Development - The long-acting follicle-stimulating hormone is expected to generate significant revenue by the year 2026 [1] - The company is currently in the process of regulatory review for the long-acting growth hormone in collaboration with Weisheng Pharmaceutical [1] - The company anticipates that both the long-acting growth hormone and the long-acting follicle-stimulating hormone will quickly enter the market, providing new growth opportunities for its business performance [1]

Summary of Jichuan Pharmaceutical Conference Call Industry and Company Overview - **Company**: Jichuan Pharmaceutical - **Industry**: Pharmaceutical, specifically focusing on Traditional Chinese Medicine (TCM) and respiratory disease treatments Core Points and Arguments - **Sales Pressure**: Jichuan Pharmaceutical is facing significant pressure in both OTC (over-the-counter) and hospital sales, particularly noted in Q2 of this year, with a substantial decline compared to the previous year [2][3] - **Seasonal Recovery**: The upcoming flu season is expected to stabilize sales for heat-clearing and detoxifying products such as Pudilan and Xiaorichiqiao [2][3] - **Future Strategy**: The company's future strategy focuses on two main areas: innovation in TCM and clearing turning points to lock in profits. Key products, Pudilan and Xiaorichiqiao, contribute 60% to 70% of the company's revenue [4] - **New Product Launches**: The long-acting flu medication launched in July is anticipated to boost sales during the flu season, while a long-acting growth hormone is expected to be launched by mid-next year [2][4] Risk Management - **Collective Procurement Risks**: Jichuan Pharmaceutical has a low risk of collective procurement for its exclusive product Pudilan, as it is primarily used in outpatient markets. Although Xiaorichiqiao faces some risks, the company has developed strategies to mitigate these, including the introduction of new models [5] - **Profit Impact**: Even in the worst-case scenario, the expected price reduction for Xiaorichiqiao is moderate, with limited impact on existing profits, corresponding to a valuation of approximately 15 times [5] Investment Considerations - **Investment Value**: Jichuan Pharmaceutical's stable cash flow and high dividend payout ratio (close to 100%) contribute to maintaining stock price stability, presenting a certain level of investment value, especially during the flu season [2][6] - **Market Expectations**: The current stock price reflects market expectations, but potential catalysts from new products and the flu season could provide opportunities for investors [6] - **Focus Areas for Investors**: Investors are encouraged to pay attention to new products in the respiratory disease sector and consider positioning themselves accordingly [6]

Core Viewpoint - Jichuan Pharmaceutical's financial performance continues to decline, with significant drops in revenue and net profit in the first half of 2025, raising concerns about the company's future prospects due to challenges from core product sales and ongoing medical procurement policies [1][2][3]. Financial Performance - In the first half of 2025, Jichuan Pharmaceutical reported revenue of 2.75 billion yuan, a year-on-year decrease of 31.9%, and a net profit of 724 million yuan, down 45.9% [2]. - The second quarter of 2025 saw revenue of 1.22 billion yuan, a decline of 25.03% year-on-year and 19.8% quarter-on-quarter, with net profit at 284 million yuan, down 42.39% year-on-year and 35.5% quarter-on-quarter [2]. Core Products and Market Challenges - The sales of Jichuan's key products, Pudilan Anti-inflammatory Oral Liquid and Children's Chiqiao Qingre Granules, have significantly decreased, with their combined sales accounting for only 49.51% of total revenue in the first half of 2025, down from 60.12% in 2024 [2][3]. - The decline in sales is attributed to changes in market demand and the impact of medical procurement policies, which have affected the pricing and availability of these products [2][4]. Historical Context - Jichuan's revenue surged from 7.63 billion yuan in 2021 to 9.655 billion yuan in 2023 due to increased demand for respiratory disease treatments, but has since fallen to a historical low in 2025 [3]. - The company's core product, Pudilan, has been removed from several provincial medical insurance catalogs, leading to decreased patient purchasing willingness [3]. Competitive Landscape - The market for Jichuan's products is becoming increasingly competitive, with numerous alternatives available, including well-known brands that pose a threat to Pudilan's market share [4][7]. - Jichuan's other important product, Rabeprazole Sodium Enteric-Coated Capsules, faces pricing pressures from national procurement policies, which could further impact its market position [4]. Strategic Initiatives and Challenges - Jichuan is attempting to diversify by entering the personal care and innovative drug markets, but results have been limited, with personal care products generating only 89 million yuan in sales in 2023 [5][6]. - The company has initiated collaborations for innovative drug development, but faces stiff competition in these areas, making it difficult to establish a strong market presence [6][7]. Research and Development Focus - Jichuan has historically prioritized marketing over research and development, with R&D expenses constituting only 5.55% of total revenue in 2024, which raises concerns about its ability to innovate effectively [6][8]. - The company has several products in the pipeline, but the competitive nature of the market poses significant challenges to their success [6][7].

Core Viewpoint - Changchun High-tech is actively enhancing its strategic adjustments and innovation investments in the pharmaceutical sector, focusing on drug research and development with a comprehensive approach to various therapeutic areas [2][3] Group 1: Financial Performance - For the first half of 2025, the company reported a revenue of 6.603 billion yuan and a net profit attributable to shareholders of 983 million yuan, with a basic earnings per share of 2.44 yuan [1] Group 2: Strategic Focus and Innovation - The company has developed multiple core technology platforms with independent intellectual property rights and international competitiveness, covering the entire process of innovative drug design, screening, evaluation, process development, and formulation research [2] - The integration of artificial intelligence technology has significantly improved research and development efficiency and innovation capabilities [2] - The company is focusing on high-demand therapeutic areas, particularly in endocrine metabolism and women's health, to support sustainable development and international strategic goals [2] Group 3: R&D Pipeline and Technology - The company is leveraging cutting-edge technologies to drive research and development innovation, establishing a differentiated pipeline for major diseases with a focus on "precise design - efficient delivery - targeted regulation" [3] - Various precision-targeted drug development technology platforms have been established, including small nucleic acid delivery, antibody and protein conjugation, and targeted resistant bacteria lytic enzyme technology [3] - The company aims to develop highly differentiated pipelines targeting key diseases in endocrine metabolism, oncology, immunology, and respiratory health, with goals of first-in-class or best-in-class products [3] Group 4: Product Development and Market Strategy - The long-acting growth hormone product is the only one approved for three major indications, supported by five years of real-world data confirming its long-term safety [4] - The company plans to expand its market presence by increasing hospital access and diversifying revenue streams from innovative drug overseas licensing and product sales [4] - Focus areas include adult growth hormone deficiency and traumatic brain injury, with an emphasis on IGF-1 screening and addressing various clinical manifestations related to growth hormone deficiency [4]